Hosted on MSN8mon
FDA lifts partial hold on Nurix Phase 1 study for NX-2127Nurix Therapeutics (NASDAQ:NRIX) said the FDA has lifted a partial clinical hold on a Phase 1 study for its drug NX-2127 in the treatment of relapsed/refractory B-cell malignancies. The clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback